a total dose of 50.4 Gy in 28 fractions over 5.5 weeks. Maintenance therapy of S-1: 80mg/m2 for 28 days, followed by a rest period of 14 days.

2 trials

Sponsors

Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Department of Gastroenterology, BELL LAND General Hospital

Conditions

Locally advanced pancreatic cancer

Phase 2

A Phase II trial of S-1 and concurrent radiotherapy for locally advanced pancreatic cancer

Active, not recruitingJPRN-UMIN000000486

Hepatobiliary and Pancreatic Oncology Division, National Cancer Center HospitalLocally advanced pancreatic cancer

Start: 2006-07-01Target: 60Updated: 2026-06-29

Unknown Phase

A clinical trial of S-1 and concurrent radiotherapy for locally advanced pancreatic cancer

RecruitingJPRN-UMIN000005420

Department of Gastroenterology, BELL LAND General HospitalLocally advanced pancreatic cancer

Start: 2011-01-01Target: 10Updated: 2026-06-29